

REFERENCES

1. Broadway-Duren JB, Cesario SK. A Systematic Review of the Literature on Systemic Lupus Erythematosus. *Journal of National Black Nurses' Association : JNBNA*. 2020;31(2):60-66.
2. Nikpour M, Bridge JA, Richter S. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need. *Intern Med J*. 2014;44(12a):1170-1179.
3. Izmirly PM, Parton H, Wang L, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. *Arthritis & rheumatology (Hoboken, NJ)*. 2021;73(6):991-996.
4. Barber MR, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Svenungsson E, Peterson J, Clarke AE, Ramsey-Goldman R. Global epidemiology of systemic lupus erythematosus. *Nature Reviews Rheumatology*. 2021 Sep;17(9):515-32.
5. Lin DH, Murimi-Worstell IB, Kan H, Tierce JC, Wang X, Nab H, Desta B, Hammond ER, Alexander GC. Health care utilization and costs of systemic lupus erythematosus in the United States: A systematic review. *Lupus*. 2022 Jun;31(7):773-807. doi: 10.1177/09612033221088209. Epub 2022 Apr 25. PMID: 35467448.
6. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. *International journal of technology assessment in health care*. 2022;38(1):e13.
7. Shah M, Chaudhari S, McLaughlin TP, et al. Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus. *Clinical Therapeutics*. 2013;35(4):486-497.
8. Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. *Journal of Medical Economics*. 2013;16(5):667-677.
9. Tkacz J, Perry A, Varker H, Bizier R, Ortmann R, Wu SSJ. Clinical and economic characterization of systemic lupus erythematosus patients: Real world observation across disease severity and payer channels in the u.s. *Arthritis and Rheumatology*. 2021;73(SUPPL 9):259-260.
10. Clarke AE, Yazdany J, Kabadi SM, et al. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States. *Seminars in Arthritis and Rheumatism*. 2020;50(4):759-768
11. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA. Total costs and predictors of costs in patients with systemic lupus erythematosus. *Rheumatology*. 2001;40(1):37-47.
12. Samnaliev M, Barut V, Weir S, et al. Health-care utilization and costs in adults with systemic lupus erythematosus in the United Kingdom: A real-world observational retrospective cohort analysis. *Rheumatology Advances in Practice*. 2021;5(3).
13. Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus tri-nation study: Longitudinal changes in physical and mental well-being. *Rheumatology*. 2005;44(6):751-755.
14. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Annals of the Rheumatic Diseases*. 2006;65(9):1175-1183.

15. Schwarting A, Friedel H, Garal-Pantaler E, et al. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. *Rheumatology and Therapy*. 2021;8(1):375-393.
16. Roman Ivorra JA, Fernandez-Llanio-Comella N, San-Martin-Alvarez A, et al. Health-related quality of life in patients with systemic lupus erythematosus: a Spanish study based on patient reports. *Clinical Rheumatology*. 2019;38(7):1857-1864.
17. Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. *Annals of the Rheumatic Diseases*. 2014;73(1):154-160.
18. Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. *Journal of Medical Economics*. 2020;23(7):786-799.
19. Narayanan S, Wilson K, Ogelsby A, Juneau P, Durden E. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. *Journal of Occupational and Environmental Medicine*. 2013;55(11):1262-1270.
20. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. *Arthritis Care and Research*. 2008;59(12):1788-1795.
21. Anandarajah AP, Luc M, Ritchlin CT. Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs. *Lupus*. 2017 Jun;26(7):756-761. doi: 10.1177/0961203316676641. Epub 2016 Nov 12. PMID: 27831537.
22. Furst DE, Clarke A, Fernandes AW, et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. *Lupus*. 2013;22(3):268-278.
23. Yelin E, Trupin L, Katz P, et al. Impact of health maintenance organizations and fee-for-service on health care utilization among people with systemic lupus erythematosus. *Arthritis Care and Research*. 2007;57(3):508-515.
24. Kabadi S, Yeaw J, Bacani AK, et al. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus. *Lupus*. 2018;27(11):1799-1809.
25. Kariburyo F, Xie L, Sah J, Li N, Lofland JH. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. *Journal of Medical Economics*. 2020;23(1):1-9.
26. Murimi-Worstell IB, Lin DH, Kan H, et al. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. *Journal of Rheumatology*. 2021;48(3):385-393.
27. Prete PE, Majlessi A, Gilman S, Hamideh F. Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. 2001;7(3):142-150.
28. Bell CF, Priest J, Stott-Miller M, et al. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: A retrospective analysis of claims data in the USA. *Lupus Science and Medicine*. 2020;7(1).

29. Furst DE, Clarke A, Fernandes AW, et al. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. *Journal of Medical Economics*. 2013;16(4):500-509.
30. Garris C, Shah M, Farrelly E. The prevalence and burden of systemic lupus erythematosus in a medicare population: Retrospective analysis of medicare claims. *Cost Effectiveness and Resource Allocation*. 2015;13(1).
31. Bartels-Peculis L, Sharma A, Edwards AM, Sanyal A, Connolly-Strong E, Nelson WW. Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population. *Open access rheumatology : research and reviews*. 2020;12:117-124.
32. Chen SY, Choi CB, Li Q, et al. Glucocorticoid use in patients with systemic lupus erythematosus: Association between dose and health care utilization and costs. *Arthritis Care and Research*. 2015;67(8):1086-1094.